Explore the vast range of titles available.

We report photometric observations of Comet 103P/Hartley 2 during its 2023 apparition. Our campaign, conducted from August through December 2023, combined data from a global network of citizen astronomers coordinated by Unistellar and the Association Française d'Astronomie. Photometry was derived using an automated pipeline for eVscope observations in partnership with the SETI Institute and aperture photometry via AstroLab Stellar. We find that the comet's peak reduced brightness, measured at \\(G_{\\rm min} = 10.24 \\pm 0.47\\), continues a long-term fading trend since 1991. The decline in activity follows a per-apparition minimum magnitude increase of \\(\\Delta G_{\\rm min} = 0.59 \\pm 0.11\\) mag, corresponding to an approximately \\(42\\%\\) reduction in brightness each return. This trend implies that the comet's active fraction has declined by about an order of magnitude since 1991 and may indicate that Hartley 2 is no longer hyperactive by definition. The fading is consistent with progressive volatile depletion rather than orbital effects. These results offer insight into the evolutionary processes shaping Jupiter-family comets.

A search for dark matter particles is performed using events with a pair of W bosons and large missing transverse momentum. Candidate events are selected by requiring one or two leptons ( ℓ = electrons or muons). The analysis is based on proton-proton collision data collected at a center-of-mass energy of 13 TeV by the CMS experiment at the LHC and corresponding to an integrated luminosity of 138 fb − 1 . No significant excess over the expected standard model background is observed in the ℓν qq and 2 ℓ 2 ν final states of the W + W − boson pair. Limits are set on dark matter production in the context of a simplified dark Higgs model, with a dark Higgs boson mass above the W + W − mass threshold. The dark matter phase space is probed in the mass range 100–300 GeV, extending the scope of previous searches. Current exclusion limits are improved in the range of dark Higgs masses from 160 to 250 GeV, for a dark matter mass of 200 GeV.

Background: Voriconazole is one of the first-line therapies for invasive pulmonary aspergillosis. Drug concentrations might be significantly influenced by the use of extracorporeal membrane oxygenation (ECMO). We aimed to assess the effect of ECMO on voriconazole exposure in a large patient population. Methods: Critically ill patients from eight centers in four countries treated with voriconazole during ECMO support were included in this retrospective study. Voriconazole concentrations were collected in a period on ECMO and before/after ECMO treatment. Multivariate analyses were performed to evaluate the effect of ECMO on voriconazole exposure and to assess the impact of possible saturation of the circuit’s binding sites over time. Results: Sixty-nine patients and 337 samples (190 during and 147 before/after ECMO) were analyzed. Subtherapeutic concentrations (<2 mg/L) were observed in 56% of the samples during ECMO and 39% without ECMO (p = 0.80). The median trough concentration, for a similar daily dose, was 2.4 (1.2–4.7) mg/L under ECMO and 2.5 (1.4–3.9) mg/L without ECMO (p = 0.58). Extensive inter-and intrasubject variability were observed. Neither ECMO nor squared day of ECMO (saturation) were retained as significant covariates on voriconazole exposure. Conclusions: No significant ECMO-effect was observed on voriconazole exposure. A large proportion of patients had voriconazole subtherapeutic concentrations.